Zurcher Kantonalbank Zurich Cantonalbank Sells 1,423 Shares of Quanterix Co. (NASDAQ:QTRX)

Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in shares of Quanterix Co. (NASDAQ:QTRX) by 18.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,260 shares of the company’s stock after selling 1,423 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Quanterix were worth $171,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. SG Americas Securities LLC increased its position in Quanterix by 150.2% during the 3rd quarter. SG Americas Securities LLC now owns 14,235 shares of the company’s stock worth $386,000 after buying an additional 8,546 shares during the period. Robeco Institutional Asset Management B.V. acquired a new position in Quanterix in the 3rd quarter worth about $67,000. Emerald Mutual Fund Advisers Trust raised its position in Quanterix by 353.4% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 313,044 shares of the company’s stock valued at $8,496,000 after purchasing an additional 243,994 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Quanterix by 7.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 16,469 shares of the company’s stock valued at $447,000 after buying an additional 1,118 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in Quanterix by 66.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 85,019 shares of the company’s stock valued at $2,307,000 after acquiring an additional 33,871 shares during the period. Institutional investors and hedge funds own 86.48% of the company’s stock.

Insider Buying and Selling

In related news, Director Laurie J. Olson sold 1,500 shares of Quanterix stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total value of $36,525.00. Following the sale, the director now owns 15,238 shares of the company’s stock, valued at approximately $371,045.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is owned by insiders.

Quanterix Stock Up 3.3 %

Shares of NASDAQ:QTRX opened at $17.36 on Wednesday. The stock has a market cap of $664.02 million, a price-to-earnings ratio of -20.19 and a beta of 1.41. The business’s 50 day moving average is $21.51 and its 200 day moving average is $23.14. Quanterix Co. has a 12-month low of $15.32 and a 12-month high of $29.70.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). The firm had revenue of $31.55 million during the quarter, compared to analysts’ expectations of $27.92 million. Quanterix had a negative net margin of 26.42% and a negative return on equity of 9.15%. As a group, equities research analysts expect that Quanterix Co. will post -1.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Scotiabank increased their target price on shares of Quanterix from $30.00 to $32.00 and gave the company a “sector outperform” rating in a research report on Monday, March 4th. Canaccord Genuity Group decreased their target price on Quanterix from $32.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, April 29th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Quanterix presently has an average rating of “Buy” and a consensus target price of $30.60.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.